基于系统综述的松龄血脉康胶囊治疗高血压、高脂血症的有效性评价

Evaluation on Effectiveness of Songling Xuemaikang Capsules in the Treatment of Hypertension and Hyperlipemia Based on Systematic Review

目的:通过方法学质量评价工具AMSTAR 2量表和证据评价等级系统(GRADE),对松龄血脉康胶囊治疗高血压、高脂血症的有效性进行系统评价。方法:检索中国知网、中国生物医学文献数据库、万方数据库、维普数据库、the Cochrane Library、PubMed、Web of Science以及Springer等数据库,纳入以松龄血脉康胶囊为研究对象的系统综述,检索时间为建库至2022年7月27日,对系统综述的研究结果进行整理归纳,采用GRADE系统评价各结局指标的质量,采用AMSTAR 2量表评价纳入文献的质量。结果:最终纳入9篇系统综述,其中8篇为松龄血脉康胶囊治疗高血压,1篇为松龄血脉康胶囊治疗高脂血症。系统综述研究结果显示,与单用化学药相比,松龄血脉康胶囊与化学药联合应用的疗效较好,主要体现在总有效率、收缩压、舒张压、总胆固醇、三酰甘油、低密度脂蛋白胆固醇和高密度脂蛋白胆固醇等指标上。GRADE评价结果显示,9个为中级证据,23个为低级证据,2个为极低级证据。AMSTAR 2量表评价结果显示,9篇文献的方法学质量均为极低。结论:松龄血脉康胶囊在治疗高血压、高脂血症方面有一定疗效,但原始文献质量偏低。建议后期开展高质量的临床随机对照试验,参照循证医学规范的评价方法,开展松龄血脉康胶囊安全性、有效性和经济性等方面的评价,以期为临床提供更高质量的证据。

OBJECTIVE:To systematically review the efficacy of Songling Xuemaikang capsules in the treatment of hypertension and hyperlipidemia by methodological quality assessment tools including AMSTAR 2 scale and grading system of evidence evaluation(GRADE).METHODS:Systematic reviews of studies with Songling Xuemaikang capsules were enrolled by retrieving databases including CNKI,CBM,Wanfang Data,VIP,the Cochrane Library,PubMed,Web of Science and Springer from base-building to Jul.27th,2022.The research results of systematic review were collated and summarized,the quality of each outcome index was evaluated by using the GRADE system,and the quality of enrolled literature was evaluated by using the AMSTAR 2 scale.RESULTS:Finally 9 systematic reviews were enrolled,8 of which were on the treatment of hypertension with Songling Xuemaikang capsules and 1 on hyperlipidemia with Songling Xuemaikang capsules.The research results of systematic review indicated that compared with pharmaceutical chemicals alone,the efficacy of Songling Xuemaikang capsules combined with pharmaceutical chemicals was better,mainly in terms of indicators such as the total effective rate,systolic blood pressure,diastolic blood pressure,total cholesterol,triacylglycerol,low density lipoprotein cholesterol and low density lipoprotein cholesterol.The results of the GRADE evaluation showed that 9 were moderate evidence,23 were low evidence and 2 were very low evidence.The results of AMSTAR 2 scale evaluation showed that the methodological quality of all 9 studies was extremely low.CONCLUSIONS:Songling Xuemaikang capsules have a certain efficacy in the treatment of hypertension and hyperlipidemia,but the original literature is of low quality.It is recommended that high-quality clinical randomized controlled trials be conducted to evaluate the safety,efficacy and economical efficiency of Songling Xuemaikang capsules with reference to the evaluation methods of evidence-based medical guidelines,so as to provide higher-quality evidence for clinical purposes.